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markers for prognosis of mortality and functional outcome. 
Within the group of prognostic markers we discuss markers 
involved in coagulation processes (e.g., D-Dimers), neuroen-
docrine markers (e.g., copeptin), systemic metabolic markers 
(e.g., blood glucose levels), markers of inflammation (e.g., IL-
6), as well as growth factors (e.g., VEGF), and others (e.g., glu-
tamate). Some of those blood biomarkers are agents of 
pathologic processes associated with hemorrhagic stroke 
but also other diseases, whereas others play more distinct 
pathophysiological roles and help in understanding the ba-
sic mechanisms of brain damage and/or recovery in ICH. 
 Key Messages: Numerous blood biomarkers are associated 
with different pathophysiological pathways in ICH, and 
some of them promise to be useful in the management of 
ICH, eventually contributing additional information to cur-
rent tools for diagnosis, therapy monitoring, risk stratifica-
tion, or intervention. Up to date, however, no blood bio-
marker of ICH has been studied sufficiently to find its way 
into clinical routine yet; well-designed, large-scale, clinical 
studies addressing relevant clinical questions are needed. 
We suggest that the effectiveness of biomarker research in 
ICH might be  improved by international cooperation and 
shared resources for large validation studies, such as pro-
vided by the consortium on stroke biomarker research 
(http://stroke- biomarkers. com/page.php?title=Resources). 
 © 2014 S. Karger AG, Basel 
 Key Words 
 Blood biomarker · Intracerebral hemorrhage · 
Management · Stroke 
 Abstract 
 Background: Intracerebral hemorrhage (ICH), a subtype of 
stroke associated with high mortality and disability, ac-
counts for 13% of all strokes. Basic and clinical research has 
contributed to our understanding of the complex patho-
physiology of neuronal injury in ICH. Outcome rates, how-
ever, remain stable, and questions regarding acute manage-
ment of ICH remain unanswered. Newer research is aiming 
at matching measured levels of serum proteins, enzymes, or 
cells to different stages of brain damage, suggesting that 
blood biomarkers may assist in acute diagnosis, therapeutic 
decisions, and prognostication. This paper provides an over-
view on the most promising blood biomarkers and their po-
tential role in the diagnosis and management of spontane-
ous ICH.  Summary: Information was collected from studies, 
reviews, and guidelines listed in PubMed up to November 
2013 on blood biomarkers of nontraumatic ICH in humans. 
 We describe the potential role and limitations of GFAP, 
S100B/RAGE, and ApoC-III as diagnostic biomarkers, β- Amy-
loid as a biomarker for etiological classification, and 27 bio-
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 Introduction 
 Epidemiology of ICH 
 Stroke annually brings 15 million patients into emer-
gency rooms worldwide, of which 5.5 million die and an-
other 5 million are left permanently disabled  [1] . Stroke 
is primarily categorized into ischemic (approximately 
87%) and hemorrhagic (approximately 13%, including 
subarachnoid hemorrhages) stroke  [2] .
 Spontaneous intracerebral hemorrhage (ICH) is asso-
ciated with poorer outcome compared to ischemic stroke 
(IS), with 30-day mortality rates of 37–52%  [2] and only 
20% of survivors returning to independent function at 
6 months  [3] . These rates have not changed over the past 
20 years  [4] .
 While high blood pressure used to account for 80–90% 
of ICH, today this number has decreased to 50%, presum-
ably as a result of efficient hypertension management  [5] 
and an increasing accuracy in the diagnosis of other eti-
ologies because computed tomography (CT) and especial-
ly magnetic resonance imaging (MRI) are more widely 
available. The gap therefore is being filled up by an increas-
ing number of long-term anticoagulation-related ICH 
(17% of ICH)  [6], for example, on the basis of vascular 
malformations, and especially cerebral microbleeds  [7] , 
which are generally associated with larger hemorrhage size 
and higher mortality. The third etiological subcategory, 
accounting for 20% of ICH, is the deposition of amyloid 
protein in cerebral arteries (cerebral amyloid angiopathy, 
CAA), causing the blood vessels to leak more easily  [5] .
 Pathophysiology of ICH 
 Advances in neuroimaging and animal models have 
improved our understanding of the pathophysiology of 
ICH on macro-, molecular, and genetic levels  [8] . By an-
alyzing the cascade of brain damage after ICH, targets for 
new therapies and future biomarkers can be identified. 
Most current theories imply a two-phase model of neu-
ronal injury with an early mechanical phase and a sub-
acute phase of inflammation and edema formation as re-
sponse to the hemorrhage  [9] , as well as the parallel acti-
vation of the neuroendocrine stress axis.
 Primary Phase: Mechanical Damage 
 Within 60 min after the insult, the blood released into 
the brain parenchyma leads to the compression of ana-
tomical structures and increased intracranial pressure, 
potentially leading to brain herniation  [10] , decreased 
blood flow, and direct mechanical destruction of axons 
and glial cells  [11] ( fig. 1 ).
 Secondary Phase: Physiological Response to 
Hematoma 
 The body reacts to the bleeding and rise of intracra-
nial pressure with different parallel mechanisms that ac-
celerate themselves and each other, increasingly com-
pounding the neurological injury ( fig. 2 ).
 One of the first responses to acute bleeding is the 
stress-related activation of the hypothalamo-pituitary ad-
renal (HPA)-axis as well as the sympathetic nervous sys-
tem (SNS)  [12] , both of which act systemically. Locally, 
glutamate is released by necrotic perihematomal neurons 
and by the ruptured vessels, leading to the accumulation 
of oxidative byproducts, further necrosis of neighboring 
cells, and early cytotoxic edema formation  [13] .
 Within the first two days, hemostatic mechanisms oc-
cur to limit the bleeding. Thrombin is released and affects 
a range of cells in the surrounding penumbra, creating 
inflammatory, neurotoxic conditions. Thrombin acti-
vates microglial cells to release inflammatory mediators, 
causes proliferation of mesenchymal cells and formation 
of scar tissue, and leads to endothelial cell dysfunction, 
resulting in hyperpermeability, disruption of blood brain 
barrier (BBB), and vasogenic edema formation  [14] .
 After several days, iron, hemoglobin, and free radicals 
are released into the hemorrhagic area, following the lysis 
of erythrocytes and clot components as part of the throm-
bin response, causing further inflammation and late ede-
ma formation  [15] .
 The last mechanism resulting from intracerebral in-
flammation and late edema is the activation of the com-
plement system. As C5a and C3a penetrate the neuronal 
tissue, local glia, mast cells, and leukocytes are activated, 
followed by the additional damage of perihematomal 
neurons, glia, and blood vessels, and further cell lysis and 
inflammation  [16] .
 Management of ICH 
 Modern ICH management including accurate diagno-
sis, effective treatment, prediction of progression, re-
sponse to therapy, and prognostication remains challeng-
ing. Management decisions are mainly based on neuro-
imaging information such as hematoma volume, location, 
and the presence and quantity of intraventricular bleed-
ing, and clinical information such as age and the Glasgow 
coma scale (GCS). These features are all represented in 
the Hemphill ICH score  [17] . As ICH is a medical emer-
gency, it would be beneficial to have a diagnostic tool ap-
plicable in pre-hospital diagnosis, early sub-typing, and 
risk stratification. Blood biomarker (BBM) research may 
be helpful.
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 Definition and Criteria for Novel Blood Biomarkers 
 BBMs are measurable products reflecting healthy or 
pathologic processes of the body. The ideal measurement 
of a BBM should be simple, quick, and preferably inex-
pensive. Therefore, a BBM should be easily measurable in 
accessible tissue, reproducible, and relatively stable 
throughout the healthy population. Depending on the use 
of the BBM, different challenges need to be addressed, 
one of the most important being that these BBMs add in-
formation to already accessible clinical or imaging infor-
mation  [18] .
 Identification and Selection of Blood Biomarkers in 
ICH  
 The classical evaluation of new candidate BBMs – and 
emphasis of this review – is based on pre-specified hy-
Phase 1: mechanical damage
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 Fig. 1. Pathophysiology of ICH Primary 
Phase: Mechanical Brain Damage. 
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potheses, searching pathophysiologic mechanisms of 
ICH for in blood measurable, involved agents. 
 Newer approaches based on genetic and molecular re-
search are fairly unbiased discovery processes. Gene ex-
pression profiling has generated diverse insights on RNA 
expression and protein and metabolite production, de-
picting changes in expression, induction, and function of 
genes in individuals with stroke. The advantage of such 
approaches is that they generate a number of potential 
markers of interest, but the difficulty is that the utility of 
each individual marker remains uncertain until further 
studies can validate the results  [19] . Proteomics and me-
tabolomics are new techniques to systematically scan 
blood from cases and controls for differentially expressed 
proteins and molecules (lipids, sugars, nucleotides, ami-
no acids), potentially revealing new disease-related par-
ticles  [20] . These methods, in opposition to genetic profil-
ing, respond more strongly to environmental influences 
and thus are dynamic in reflecting current physiologic 
states  [21] . Genetic and molecular technologies belong to 
the very first discovery phase of BBM research as an enor-
mous flood of information is generated, which needs ver-
satile elaborate analysis to select those agents possibly 
meaningful for further studies.
 While we recognize that cerebrospinal fluid biomark-
ers may have certain advantages over blood biomarkers, 
we focus this review on blood biomarkers alone because 
they are more readily measured repeatedly; there are a 
large number of studies addressing blood biomarkers, 
and space is limited.
 Search Methods 
 A comprehensive literature search was conducted on 
PubMed up to November 2013, including citation and 
reference tracking to identify the blood biomarkers cited 
in this review. The search terms employed were: ‘ICH’, 
‘intracerebral h(a)emorrhage/h(a)ematoma’, ‘h(a)emor-
rhagic stroke’ + ‘biomarker(s)’ + ‘management’, ‘out-
come’, ‘prognosis’, ‘diagnosis’, and ‘etiology’. With this 
retrieval strategy a total of 186 manuscripts was yielded.
 Clinical Implementation of ICH Blood Biomarkers 
 Diagnostic Blood Biomarkers 
 Diagnostic BBMs should be able to reliably distinguish 
between patients suffering from ICH, IS, and stroke mim-
ics such as seizures, migraines, syncope, or metabolic con-
ditions  [22] , enabling rapid medical interventions. This 
information is required shortly after symptom onset be-
cause early neurological damage within the first few hours 
after stroke is strongly associated with poor long-term 
outcome  [23] . BBMs differentiating ICH from IS already 
in the ambulance might be especially useful to start blood 
pressure lowering therapies in a very early stage (as sug-
gested by the results of the INTERACT2 trial  [24] ).
 Etiologic Blood Biomarkers 
 Etiologic BBMs should allow differentiation between 
bleeding based on hypertension, long-term anticoagula-
tion, CAA or other more infrequent causes. Such BBMs 
could increase the quality of rapid specific treatment, 
which differs according to the pathogenesis (blood pres-
sure control, immediate cessation of anticoagulant ther-
apy, hemostatic therapy depending on the drug used, 
and/or surgical hematoma evacuation). Etiologic BBMs 
should be found in blood sampled at admission as only 
early information can lead to early therapy.
 Blood Biomarkers of Prognosis 
 Prognostic BBMs have the potential to predict end-
points like complications, mortality, or poor functional 
outcome, and therefore may enable preventive and thera-
peutic interventions  [25] . Moreover, to later allow the in-
tegration of a BBM into the package of clinical instru-
ments, its ability to depict specific causes of worsening 
(e.g., infection, pneumonia, epileptic seizures, hemato-
ma  growth), and prognosis-related situations that allow 
specific intervention, is crucial. For example, early time 
to surgery (excluding emergency decompression) was 
shown to improve mortality rates but also increase the 
risk of rebleeding. Sixty percent of ICH patients are at a 
low risk for further bleeding, and might therefore qualify 
for surgery, whereas patients with a high risk of rebleed-
ing might benefit more from medical intervention only 
 [26–28] . A BBM reliably discriminating the low risk from 
the high risk-rebleeding group would be very useful for 
the intervention triage. Depending on the time-point of 
blood withdrawal, prognostic BBMs could also enable 
early risk stratification, emergency health care decisions, 
and late interventions, such as rehabilitation and follow-
up care. As prognostic BBMs correlate in an either pro-
tective or damaging way with disease progression, they 
might also help in identifying new therapeutic targets.
 Blood Biomarkers as Surrogates 
 Surrogate markers are markers that substitute for true 
end points. This correlation needs to show a robust stabil-
ity across different beneficial as well as aggravating inter-
ventions and alterations of circumstances, before a change 
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of the biomarker might actually reliably predict the clini-
cal outcome (in place of the clinical outcome itself) and 
therefore account as surrogate  [29] . This high bar is set to 
prevent misleading information regarding the true end 
point by a ‘surrogate’ and is a tall order for any blood test. 
None of the BBMs mentioned below serves as such a good 
marker of change in disease status that it could be used in 
place of other measures (yet).
 The most advanced BBM examples for each category 
are summarized in  table 1 .
Selection of Blood Biomarkers in ICH
 Blood Biomarkers for Diagnosis 
 GFAP 
Glial fibrillary acidic protein (GFAP) is an intermedi-
ate filament expressed by astrocytes and ependymal cells. 
After ICH it can be found in serum of patients due to ne-
crotic brain cell destruction and BBB disruption. Low 
concentrations of GFAP are found in the blood of healthy 
controls;  [30] it is increased after IS, but the highest con-
centrations are found in early ICH patients  [31] .
 In a recent multicenter cohort study including 205 pa-
tients diagnosed with either IS, ICH, or stroke mimics, 
plasma GFAP on admission had a sensitivity of 84% and 
specificity of 96% for differentiating ICH from IS and 
stroke mimics (AUC 0.915, 95% CI 0.847–0.982)  [32] .
 Since this study only included patients with hemi-
spheric stroke symptoms, the results cannot be general-
ized to all ICH patients. This also may have led to a high-
er sensitivity. Furthermore, only few mimics were includ-
ed, potentially causing artificial increase of specificity.
 S100B/RAGE
 The transmembrane Receptor for Advanced Glycation 
Endproducts (RAGE) is a multiligand member of the im-
munoglobulin superfamily, which plays a major role in 
both early development and progression of atherosclero-
sis and vascular inflammation  [33] . S100B is a brain-spe-
cific, calcium-binding protein and ligand for RAGE, ex-
pressed and released mainly by astrocytes  [34] . S100B/
RAGE interactions might show different expression 
courses in inflammatory or hypoxic brain damage.
 A large study recently showed the ability of the S100B/
RAGE BBM panel to distinguish between IS and ICH in 
a sample of 915 stroke patients (AUC 0.76)  [35] . In blood 
sampled within 6 h from symptom onset, S100B was el-
evated, whereas sRAGE was lower in ICH patients com-
pared to patients with IS. The additive value of the panel 
to the AUC when added to the model using only clinical 
signs was significant (AUC 0.84 vs. AUC 0.77) and even 
stronger when measured earlier (<3 h from stroke; AUC 
0.81 vs. AUC 0.76)  [35] .
 Although promising, the dynamics of sRAGE in stroke 
is not yet clearly understood. The results need validation 
in larger cohort studies including different settings, stroke 
mimics, and additional BBMs.
 ApoC- III
 ApoC-III is a member of the apolipoprotein family ex-
pressed by the liver. It is found mainly in very-low-den-
sity lipoprotein (VLDL) particles and is associated with 
cardiovascular risk.
 In a small case-control study that measured ApoC-III 
expression in stroke patients within 6 h from symptom 
onset, a relative overexpression of ApoC-III was found in 
IS compared to ICH patients. ApoC-III levels allowed dif-
ferentiation of ICH from IS with 94 sensitivity and 87% 
specificity and distinguished ICH from healthy controls 
with 100% sensitivity and 67% specificity  [36] .
 So far, ApoC-III seems to be an interesting marker to 
distinguish ICH from IS, but the sample size was small 
and data was not collected prospectively. A larger valida-
tion study should also include stroke mimics.
 Blood Biomarkers for Etiological Classification 
 β-Amyloid
 β-Amyloid (βA) is a protein pathologically deposited 
in smaller arteries of the brain of patients suffering from 
CAA, causing them to leak or rupture more easily  [37] .
 By comparing plasma of CAA-related ICH patients to 
healthy controls, it was shown that βA was significantly 
higher in CAA cases than in controls. βA levels even dif-
ferentiated between patients with probable CAA and 
those diagnosed with possible CAA (p < 0.015) or con-
trols (p < 0.005)  [38] . The development of a βA screening 
method for CAA would be particularly useful, as diagno-
sis of CAA prior to hemorrhage is not yet possible  [39] . 
Confirmation in a prospective multicenter study is indis-
pensable, as the sample size was small and a previous 
study showed contradicting results  [40] .
 Blood Biomarkers for Prognosis and as 
Pharmacological Targets 
 MMP-9
 Matrix metalloproteinase 9 (MMP-9) is a protease in-
duced by thrombin and blood, which increases capillary 
permeability, disrupts BBB, and is neurotoxic by de-
grading the endothelial basal lamina and extracellular 
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matrix  [41, 42] . On the other hand, MMP-9 contributes 
in beneficial ways by promoting angiogenesis, remodel-
ing, cell migration, and phagocytosis  [43] .
 In a small cohort study, MMP-9 was found to be ele-
vated after ICH  [44] . In cases of deep bleeding, MMP-9 is 
significantly correlated with edema size and neurological 
worsening. Another larger cohort study found high 
MMP-9 levels correlate with a percentage of hematoma 
growth (r = 0.64)  [45] .
 MMP-9 seems to play an important role in complica-
tions after ICH  [46] . Its role as a predictor of hematoma 
growth needs validation in larger studies. If validated, 
MMP-9 may play a role in selecting patients for trials in-
vestigating hemicraniectomy in ICH.
 BNP
 B-type natriuretic peptide (BNP) is a hormone secreted 
by the smooth muscle cells of the heart when stretched 
 [47] . Recent research  [48] suggests that BNP plays a role 
in disease progression of neuronal injuries including ICH.
 In a small cohort study, BNP levels correlated with the 
ICH score (r = 0.42) and independently predicted out-
come at discharge  [49] .
 The mechanisms by which endogenous high BNP lev-
els are related to disease progression after ICH are not yet 
understood and require further research.
 VAP-1/SSAO
 Vascular adhesion protein-1 (VAP-1) belongs to the 
semicarbazide-sensitive amine oxidase (SSAO) family, en-
zymes involved in the process of immune cell migration, 
and found either on the cell surface or soluble in serum.
 In ICH patients, low VAP-1 independently predicted 
neurological improvement after 48 h (OR = 6.8) after ac-
counting for baseline stroke characteristics  [50] . This 
supports the finding that inhibition of VAP-1 activity in 
mice reduced brain cell destruction  [51] .
 VAP-1 shows potential as an outcome predictor, 
which needs to be verified in future studies also including 
stroke mimics. Moreover, comparing VAP-1 activities 
with other important predictors of outcome, such as ICH 
volume and early hematoma growth, are required.
 s-Fas
 Soluble Fas (s-Fas) are variant molecular splicing 
products of the Fas-receptor/ligand apoptosis signaling 
pathway, and they belong to the tumor necrosis factor 
(TNF) receptor family. Some s-Fas molecules were found 
to be potential inhibitors of the Fas-apoptosis system, and 
appear to correlate with neuronal cell death  [52] .Ta
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 It was shown that s-Fas is significantly lower in ICH 
patients than in healthy controls, when blood is with-
drawn within 24 h from symptom onset. Moreover, low 
baseline s-Fas proved to be an independent predictor for 
perihematomal edema growth (OR = 0.125)  [53] . Admin-
istration of s-Fas  [54] inhibits the Fas-receptor/ligand 
system in a cell model  [55] , reducing neuronal damage.
 These findings should further be elucidated, especially 
the role of the Fas system in cell death after ICH.
 S100B
 By inducing neuronal death, S100B stimulates inflam-
matory stress as well as dispersal of interleukins (IL-1 
 [56] , IL-6) and TNFα  [57] and therefore might correlate 
with disease progression.
 In a small case-control study, plasma S100B was found 
to be significantly increased from symptom onset until 
day 3 in patients with ICH compared to healthy controls. 
It was an independent predictor for 1-week mortality 
 [58] . Similarly, another study showed S100B to be an in-
dependent predictor for neurological functional outcome 
at discharge in a small cohort of ICH patients  [49] . The 
predictive value of S100B alone (AUC = 0.88) was slight-
ly lower compared to areas under the curve of GCS scores 
(AUC = 0.94) and ICH volume (AUC = 0.93)  [58] .
 There is a potential use of S100B as an outcome BBM 
but it needs verification in larger prospective cohort stud-
ies. Moreover, if S100B does not provide incremental val-
ue for prognostication in ICH, it might not find its way 
into clinical routine.
 Blood Glucose Level
 A large-scale cohort study showed a significant rela-
tionship between blood glucose levels (BGL) on admis-
sion and 30-day mortality. Even after excluding patients 
with diabetes, BGL proved an independent risk factor for 
death (adjusted HR = 1.10, 95% CI 1.01–1.19). BGL re-
measured at 30 days revealed increase in long-term mor-
tality with each glucose quartile  [59] .
 These results imply the importance for early BGL 
monitoring in ICH patients, but need to be taken care-
fully as management of glucose-levels has been proven 
delicate in other critically ill patients  [60] . Early interven-
tion studies need to evaluate the ideal range for glucose 
levels after ICH.
 Inflammatory Markers
 As part of the inflammatory response, cytokines 
(TNFα, IL-6, IL-10, and IL-11), acute phase proteins 
(CRP), immune cells (peripheral leukocytes), ICAM (a 
member of the immunoglobulin superfamily), and High-
Mobility-Group-Protein B1 (HMGB1, is a pro-inflam-
matory, DNA-binding protein released by micro glia 
 [61] ) play variable roles in the progress of ICH, being in-
volved in the rupture of vessels, further bleeding and ne-
crosis, but in the subsequent course also acting to pro-
mote recovery. Consequently, many of them correlate 
with severity of stroke in the acute phase.
 TNFα, ICAM-1, IL-6, IL-10, IL-11 .  In a small cohort, 
increased plasma TNFα on day 1 was found to predict 
intensive care unit (ICU) mortality  [62] . High TNFα and 
IL-6 levels both proved independent predictors for early 
hematoma growth in ICH patients and were associated 
with increased risk of mortality and poor functional out-
come at 3 months  [45] . Another cohort study showed that 
TNFα, IL-6 and intercellular adhesion molecule 1 (ICAM-
1) independently correlated with hypodensity on CT at 
days 3–4. In this study, ICAM-1 was also shown to cor-
relate with poor outcome at 3 months and with residual 
cavity size  [63] . In a prospective study enrolling 59 con-
secutive ICH patients, IL-10 predicted rebleeding with 
75% sensitivity and 72% specificity and independently 
predicted poor 30-day functional outcome with 73% sen-
sitivity and specificity of 66%  [64] . Serum IL-11 was 
found to be significantly higher in nonsurvivors of a small 
ICH cohort on days 2–4  [65] .
 CRP .  In a large ICH cohort, elevated blood C-reactive 
protein (CRP) was independently associated with in-
creased 30-day mortality after ICH and even added an 8% 
improvement to the accuracy of the Hemphill score mod-
el  [66] .
 HMGB-1 .  In a small case-control study, comparing 
ICH patients to healthy controls, higher plasma HMGB-1 
levels measured within the first 12 h were associated with 
poor outcome. The study also showed significant correla-
tion of HMGB-1 with levels of IL-6 and TNFα and NIHSS 
(r = 0.845) score at day 10  [67] .
 Peripheral Leukocyte Count .  In a case-control study, 
the change of peripheral leukocyte count (LcC) was exam-
ined by measuring the difference between LcC on admis-
sion and the highest LcC in the first 72 h. The study showed 
significant correlation between LcC and poorer discharge 
disposition (OR = 1.258) as well as decline in modified 
Barthel index (MBI) at three months (r = 0.222)  [3] . An-
other prospective study showed higher LcC in patients re-
bleeding within 30 days  [64] .
 The mechanisms of brain tissue damage from blood 
vessel rupture, disruption of the BBB, edema formation, 
and activation of the inflammatory response system are 
not yet completely understood. Inflammation may con-
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tribute to neurological damage in the beginning but con-
tribute to recovery in late ICH. Larger cohort study de-
signs are necessary, especially for usage in clinical prog-
nostic decisions, to validate these findings over the 
long-term as these markers follow a dynamic course.
 CD34+ Progenitor Cells, VEGF, Ang-1, G-CSF 
 CD34+ progenitor cells (CD34) in the blood are circu-
lating ancestors of adult endothelial cells and play an im-
portant role in angiogenesis. Vascular endothelial growth 
factor (VEGF), Angiopoietin 1 (Ang-1) and granulocyte-
colony stimulating factor (G-CSF) are growth factors 
(GF) also participating in neoangiogenesis. Assuming a 
connection between effective neurovascularization and 
good recovery from hemorrhage, they were evaluated as 
potential prognostic markers.
 CD34.  In blood sampled from 32 ICH patients within 
12 h from symptom onset and on day 7, CD34 levels at 
day 7 but not day 1 positively correlated with good func-
tional outcome (OR = 1.17) and negatively with residual 
cavity volume at 3 months (r = –0.607)  [68] . A strong cor-
relation was also found between CD34 levels and GFs at 
day 7.
 VEGF, Ang-1, G-CSF. In a previous cohort study mea-
suring GF levels of 95 patients with primary ICH on 
day 3, independent associations between VEGF, Ang-1 
and G-CSF and neurologic improvement (OR = 11.2; 14.7 
and 19.6, respectively) as well as reduced residual cavity 
size at 3 months were demonstrated  [69] .
 The results show that CD34 and GFs are not markers 
usable in the acute phase of ICH. But as their increase fol-
lowing ICH may be associated with a better functional 
outcome, further investigation of long-term dynamics 
of CD34 and GFs and their role in the healing process is 
warranted.
 Glutamate 
 Glutamate is an important neurotransmitter of the 
healthy CNS and is pathologically released in excitotoxic 
quantities by necrotic astrocytes as they appear in ICH. A 
correlation with secondary damage after ICH is expected.
 Glutamate was shown to independently predict poor 
neurologic outcome at 3 months and to positively corre-
late with residual cavity size in a cohort of 124 ICH pa-
tients (r = 0.846)  [63] .
 As glutamate has been well studied in other contexts, 
it might offer treatment opportunities after ICH, by inhi-
bition of its excitotoxic signaling pathways. Such specula-
tions and its prognostic value need to be confirmed in 
larger intervention studies.
 Ferritin 
 Free ferritin in the brain occurs in line with hemolysis 
of the escaped erythrocytes after ICH. The release of iron 
is assumed to lead to delayed brain edema formation by 
harming neuronal tissue via oxidative stress, glutamate 
release, and inflammatory response  [8, 70] .
 In a prospective study, an independent association be-
tween free serum levels of ferritin on admission and poor 
outcome has been shown (stroke severity, ICH, and ede-
ma volumes all r > 0.60)  [70] . No correlation to other 
acute phase proteins was found, even after adjustment for 
signatures for acute inflammation. The authors therefore 
suggest that free baseline ferritin affects outcome directly, 
and they propose a link to the therapeutic opportunity of 
iron chelation, which however needs further investiga-
tion.
 LDL-Cholesterol 
 Low-density lipoprotein (LDL) is involved in the 
transportation of lipid molecules (e.g., cholesterol). Al-
though high levels are a risk factor for cardiovascular 
events, after stroke, low LDL and total cholesterol levels 
are associated with unfavorable outcomes. It may be that 
serum cholesterol is needed for the integrity of vessel 
walls and that lower levels decrease platelet aggregation 
thus predisposing for ICH growth  [71] .
 A recent cohort study demonstrated an independent 
correlation between low LDL levels and hematoma 
growth at 24 h (OR = 4.24), and between early neurolog-
ical deterioration (OR = 8.27) and mortality at 3 months 
(OR = 6.34). In this study, pretreatment with statin did 
not seem to have an influence  [71] . In earlier studies, it 
was shown that low LDL-cholesterol and low total-cho-
lesterol levels predict a higher risk for mortality after ICH 
 [72–74] .
 Although LDL seems to be a strong and independent 
predictor, the study does not provide information on the 
additive value compared to other prognostic scores. 
There is a risk for selection bias due to exclusion of pa-
tients who were either comatose, who died before follow-
up CT, underwent surgery, or were under anticoagulant 
therapy  [71] .
 Coagulation Markers 
 D-Dimers are degradation products of fibrinolysis; 
fibrinogen, an acute phase protein, and Factor XIII par-
ticipate in blood clot formation. Following ICH their 
blood concentrations change, as the hemostatic system 
is activated  [75] and might allow prognostic informa-
tion.
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 D-Dimers. In a cohort study, high plasma D-Dimer 
levels proved a risk factor for 30-day mortality with a sen-
sitivity of 70% and a specificity of 60%. Moreover, an as-
sociation between D-Dimer levels and GCS score, mid-
line shift, and subarachnoid extension of the hemorrhage, 
but no association with intraventricular involvement was 
shown  [76] .
 Fibrinogen. Fibrinogen was found to be an indepen-
dent predictor of age, sex, and time from onset to inclu-
sion and Canadian Stroke Scale for early neurologic dete-
rioration (OR = 5.6) in 266 ICH patients  [77] .
 Factor XIII. One study showed increased Factor XIII 
activities in patients with growing hematomas, and de-
creased levels in the nongrowing hematoma group  [78] .
 The studies show several associations between coagu-
lation agents and other outcome predictors. Yet at the 
best cut-off levels, specificity of D-Dimers was rather 
moderate. Further research in understanding the role of 
coagulation-related markers in ICH patients is needed.
 Copeptin 
 Copeptin is the C-terminal part of pro-vasopressin, a 
neuroendocrine stress marker. As ICH is a major stressor, 
it activates the neuroendocrine stress axes and since co-
peptin has been associated with unfavorable outcome in 
patients with IS, it may also be associated with outcome 
in ICH patients  [79] .
 Copeptin – measured within 72 h from symptom onset 
in a small ICH cohort – was found to positively correlate 
with hematoma volume and negatively with the GCS. More-
over, high levels of copeptin allowed prediction of 30-day 
mortality (AUC of 0.88) and poor functional outcome at 90 
days (AUC of 0.68)  [80] . In a larger study, it was shown that 
copeptin independently predicted 1-year mortality and 
poor outcome as well as early neurologic deterioration  [81] .
 The studies demonstrate copeptin’s potential role as a 
BBM for risk stratification.
 HSP-70 
 Heat shock protein 70 (HSP-70) is involved in the pro-
cess of protein folding and helps to protect cells from 
stressors including hypoxia or temperature, as occur also 
in the brain tissue of ICH patients  [82] .
 In a small study, HSP-70 levels measured on the first 
day after ICH were found to be higher in nonsurvivors 
than in survivors  [62] .
 HSP-70 shows some potential as a prognostic marker, 
but no additive value of HSP-70 to conventional outcome 
predictors like the Hemphill grading scale have been 
shown so far.
 Plasma Microparticle Concentrations 
 Microparticles (MPs) are small membrane particles, re-
leased by stressed cells under conditions like apoptosis, 
chemical, or endotoxin stimulation  [83] . They seem to play 
a role in coagulation  [84] as well as inflammation  [85] , both 
contributing strongly to neuronal damage after ICH.
 Plasma MPs independently predicted 7-day mortality 
with a 91% sensitivity and 69% specificity. Plasma MP 
levels during the first week were higher in patients suffer-
ing from intraventricular hemorrhage, in patients with 
lower GCS scores or greater ICH volumes. Moreover, the 
study showed that increased MP levels correlated with 
higher plasma levels of acute phase response markers 
such as CRP, D-Dimers, fibrinogen, and BGL  [86] .
 Plasma MPs are potential BBMs for the severity of ear-
ly brain injury after ICH. Interest of future studies should 
be given to the origin of the measured plasma MPs to en-
hance our understanding of the cell types involved in ce-
rebral injury.
 Selection of Most Interesting Candidates 
 Blood Biomarkers Selecting Patients for Specific 
Treatment Options 
 The INTERACT2 study suggests that acute blood 
pressure–lowering therapies (<140 mm Hg) ameliorate 
outcome for ICH patients  [24] . BBMs with promising re-
sults addressing early pre-hospital identification of ICH 
versus IS are GFAP and to some degree S100B/RAGE. If 
results can be confirmed in larger samples also including 
mimics and different settings, these BBMs as point-of-
care tools could potentially facilitate early decisions on 
blood pressure therapy.
 It seems interesting to consider whether ICH patients 
could be further subdivided into groups profiting/not 
profiting from intensive blood pressure lowering or he-
mostatic interventions during hospitalization. There are 
two trials (n = 339  [87] and n = 841  [88] ) showing sig-
nificant reduction of hemorrhage size after the adminis-
tration of recombinant active factor VII (rFVIIa), but 
nevertheless fail to demonstrate an overall improved out-
come. They propose that patients that were not at risk to 
experience further expansion of hematoma should have 
been excluded to result in improved outcomes. Blood lev-
els of several BBMs (e.g., MMP-9, IL-10, see  table 2 ) in 
ICH show an ability to detect patients at risk for further 
hemorrhage and might have an importance in selecting 
patients that would profit from therapies diminishing he-
matoma growth ( table 2 ).
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 Also surgical interventions (e.g., hemicraniectomy or 
minimally invasive procedures) require stability of the 
patient’s condition in regard to further bleeding, to pos-
sibly show a better overall outcome  [26] . The above-men-
tioned BBMs that depict risk of further hemorrhagic ac-
tivities ( table 2 ) might be of use to enroll ICH patients to 
either medical or surgical intervention. Possibly, a com-
bination of those BBMs might be used for the triage, but 
so far no study has addressed this specific question.
 Only randomized controlled trials comparing algo-
rithms with and without the information of BBM values 
could answer this question.
 Selection of Blood Biomarkers Providing Strong 
Clinical Evidence 
 Study Design 
 As the research interest for BBMs in ICH evolved only 
over the last decade, the concerning studies reside still in 
an exploratory phase. Many studies are conducted in a 
case control design, which bears the problem of selection 
bias per se. Only few cohort studies, and no randomized 
controlled trials based on BBMs have been conducted.
 Study Population 
 The selection of samples and controls is crucial for the 
interpretation of the data. Current studies of BBMs in 
ICH often used healthy controls for comparison or they 
excluded clinically important comorbidities from sam-
ples and controls, which most probable – if included – 
would impair the results of the discussed markers. It is 
therefore remarkable, that the ICH sample for VAP-1/
SSAO didn’t exclude systemic diseases (i.e., severe liver 
disease), although comparing to healthy controls. The 
marker ApoC-III, on the other hand, is the only case con-
trol study, that included orthopedic patients as controls 
(without any known peripheral/central nervous system 
condition), and not healthy subjects. The only study dif-
ferentiating stroke mimics is the cohort for GFAP.
 Sample Size 
 Also sample size is an important issue and there is 
clearly need for verification of the results of most dis-
cussed BBMs in larger studies. Only few markers were 
studied in rather large samples, that is, BGL (cohort of 
1387 ICH patients), S100B/RAGE (cohort of 139 ICH 
and 776 IS cases), peripheral LcC (cohort study with 423 
ICH patients), fibrinogen (cohort study with 266 ICH pa-
tients), CRP (cohort study with 210 ICH cases), and 
GFAP (cohort study with 39 ICH, 163 IS, 3 mimics). 
However, validation studies in larger multi-center set-
tings are necessary also for these BBMs.
 Time from Symptom Onset 
 When interpreting the results, it is worth taking into 
account the particular time of blood withdrawal and the 
time from symptom onset; both these times should be 
predefined, as BBMs might follow a dynamic change, 
therefore altering information or losing comparability 
over time. BBMs that were measured at multiple pre-
defined time points are S100B, TNFα, IL-11, HSP-70, mi-
croparticles, peripheral LcC, ferritin, and GFs, and there-
fore, allow a more detailed interpretation of the predictive 
or diagnostic values at given time-points.
 Additional Value and Comparison to Clinical 
Standards 
 A new prognostic BBM generally needs to provide ad-
ditional information to established clinical features like the 
GCS, the ICH score or imaging data. S100B for example 
shows a predictive value for 1-week-mortality, that lies 
slightly (on a not significant level) below the values of the 
GCS score and ICH volume  [58] . An integration to show 
the additive value to such clinical signs would be interest-
ing, as it has been done for the panel of S100B/RAGE to 
distinguish between patients suffering from ICH versus 
IS  [35] . In this study, an additive value of the panel to the 
AUC when added to a model using only clinical signs was 
significant (AUC 0.84 vs. AUC 0.77). Also HSP-70 was test-
ed in terms of its additive value to conventional outcome 
predictors, unfortunately with no significant result  [62] .
 Blood Biomarkers Interestingly Linked to 
Pathophysiology of ICH 
 As a BBM, copeptin – the C-terminal of pro-vasopres-
sin – correlates negatively with the GCS, and positively 
with poor functional outcome, mortality, and hematoma 
size. A study investigating the inhibition of the arginine 
vasopressin (AVP) V1 receptor in mice after ICH, could 
thereby demonstrate a significant reduction in cerebral 
Table 2.  Biomarkers detecting patients suitable for surgery
Blood biomarkers predicting further bleeding
Low LDL Associated with hematoma growth at 24 h
High Factor XIII Found in patients with growing hematomas
High LcC Associated with rebleeding within 30 days
High TNFα and
IL-6
Both proved independent predictors for 
early hematoma growth
High IL-10 Found to predict rebleeding
High MMP-9 Correlates with early hematoma growth
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edema formation and significantly less neurobehavioral 
deficit in the mice treated with the competitive receptor 
antagonist  [89] . They suggest AVP might be a key player 
of water homeostasis in the brain. Also in a mouse model, 
VAP-1 (associated with bad outcome in humans) inhibi-
tion was shown to reduce brain cell destruction, most 
likely because it precludes leukocytes from migrating into 
the injured area, thereby decreasing edema formation 
 [51] . Also s-Fas administration reduced cell-death in a 
cell model, suggesting a potential therapeutic application 
of s-Fas  [55] . Similarly, another study in rats demonstrat-
ed a neuroprotective effect of deferoxamine, an iron che-
lator, in reducing post ICH edema and neurological in-
jury  [90] , which underlines the aggrieving role of ferritin 
in disease progression after ICH, suggesting a potential 
treatment opportunity of iron chelation in humans. As a 
BBM, BNP correlates with the ICH score. A recent study 
showed, that its administration in mice after traumatic 
brain injury or ICH significantly improved functional 
outcome  [91] . In the mice treated with BNP, inflamma-
tory markers (TNFα, IL-6) decreased, microglia was acti-
vated, and neuronal damage was reduced, whereas func-
tional performance and cerebral blood flow were in-
creased  [91] . It might be that in more severe ICH cases 
more BNP is released to improve the recovery, but that 
the chances of recovery are low due to the initial severity 
of the ICH. How to translate the effect of BNP in the re-
covery after ICH in mice to human beings where elevated 
BNP levels are associated with unfavorable outcome is, 
however, not yet clear. Such additional results from ani-
mal or cell models can add valuable patho-mechanistic 
information, and inspire further research hypothesis.
 Conclusions 
 Different approaches and new research, ranging from 
genomics over proteomics to classical hypothesis-based 
biomarker identification, on which we focused in this re-
view, suggest novel BBMs. Novel BBMs that correlate 
with different ICH-related processes might at some point 
improve the management and outcome of ICH patients. 
We outlined how each agent is linked to clinical assess-
ment, therefore potentially advancing the current tools 
for diagnosis, therapy monitoring, risk stratification, or 
intervention. Nevertheless, for implementation into clin-
ical routine, larger, well-designed prospective studies will 
be needed to validate findings and prove utility and ben-
efit of the cited BBMs in addition to available treatment 
protocols and adjuvants like imaging or clinical scores. In 
this stage of research where large validation studies are 
needed, effectiveness might be improved by international 
cooperation and shared resources, such as those provided 
by the consortium on stroke biomarker research (http://
stroke-biomarkers.com/page.php?title=Resources).
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